Twist Bioscience Corporation (TWST)

About Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Latest reported results

Twist Bioscience Corp. reported revenue of $118.4 million for Q3 FY2026, up 23.2% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 327 institutions reported holding TWST, with 76.4 million shares worth $7.9 billion in aggregate. The largest reported holders were Vanguard, BlackRock and Artisan Partners. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.

More on TWST

• TWST sentiment: whether news and social coverage of Twist Bioscience Corporation leans bullish or bearish, and the stories driving it.
• TWST ownership: all 327 reporting institutions, plus insider and congressional trades.
• TWST financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.

SentiSense also tracks daily options readings for Twist Bioscience Corporation: IV rank, put/call percentile, 25-delta skew and open-interest walls.

Frequently asked questions